IDRA
Income statement / Annual
Last year (2022), Idera Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Idera Pharmaceuticals, Inc.'s net income was -$23.36 M.
See Idera Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$1.45 M |
$662,000.00 |
$902,000.00 |
$16.20 M |
$249,000.00 |
$73,000.00 |
$47,000.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$1.45 M
|
$662,000.00
|
$902,000.00
|
$16.20 M
|
$249,000.00
|
$73,000.00
|
$47,000.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$12.19 M
|
$16.38 M
|
$24.77 M
|
$34.85 M
|
$41.84 M
|
$50.65 M
|
$39.82 M
|
$33.70 M
|
$27.49 M
|
$10.48 M
|
| General & Administrative Expenses |
$12.21 M
|
$9.98 M
|
$11.92 M
|
$12.48 M
|
$15.42 M
|
$16.72 M
|
$15.13 M
|
$15.40 M
|
$11.33 M
|
$7.74 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.21 M
|
$9.98 M
|
$11.92 M
|
$12.48 M
|
$15.42 M
|
$16.72 M
|
$15.13 M
|
$15.40 M
|
$11.33 M
|
$7.74 M
|
| Other Expenses |
$8.28 M
|
$1.32 M
|
$0.00
|
$181,000.00
|
$4.36 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$32.68 M
|
$27.67 M
|
$36.69 M
|
$47.33 M
|
$57.26 M
|
$67.37 M
|
$54.96 M
|
$49.10 M
|
$38.83 M
|
$18.22 M
|
| Cost And Expenses |
$32.68 M
|
$27.67 M
|
$36.69 M
|
$47.33 M
|
$57.26 M
|
$67.37 M
|
$54.96 M
|
$49.10 M
|
$38.83 M
|
$18.22 M
|
| Interest Income |
$0.00
|
$9,000.00
|
$165,000.00
|
$1.15 M
|
$1.09 M
|
$574,000.00
|
$415,000.00
|
$357,000.00
|
$0.00
|
$0.00
|
| Interest Expense |
$204,000.00
|
$7,000.00
|
$3,000.00
|
$0.00
|
$11,000.00
|
$50,000.00
|
$80,000.00
|
$105,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.66 M
|
$22,000.00
|
$61,000.00
|
$120,000.00
|
$432,000.00
|
$746,000.00
|
$656,000.00
|
$488,000.00
|
$206,000.00
|
$137,000.00
|
| EBITDA |
-$27.82 M |
$98.12 M |
-$112.60 M |
-$56.40 M |
-$59.44 M |
-$65.19 M |
-$37.65 M |
-$47.96 M |
-$38.44 M |
-$18.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
-38.95
|
-89.79
|
-72.27
|
-2.32
|
-192.62
|
-526.52
|
-384.87
|
| Operating Income Ratio |
0
|
0
|
0
|
-31.81
|
-92.08
|
-73.69
|
-2.39
|
-196.17
|
-530.85
|
-386.57
|
| Total Other Income/Expenses Net |
-$1.86 M
|
$125.76 M
|
-$75.98 M
|
-$10.45 M
|
$1.08 M
|
$483,000.00
|
$368,000.00
|
$291,000.00
|
$110,000.00
|
-$57,000.00
|
| Income Before Tax |
-$29.68 M
|
$98.09 M
|
-$112.66 M
|
-$56.52 M
|
-$59.88 M
|
-$65.98 M
|
-$38.39 M
|
-$48.56 M
|
-$38.64 M
|
-$18.23 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-39.03
|
-90.45
|
-73.15
|
-2.37
|
-195
|
-529.34
|
-387.79
|
| Income Tax Expense |
-$6.32 M
|
$7,000.00
|
-$75.97 M
|
-$10.45 M
|
$1.09 M
|
$533,000.00
|
$448,000.00
|
$396,000.00
|
$110,000.00
|
-$57,000.00
|
| Net Income |
-$23.36 M
|
$98.08 M
|
-$112.66 M
|
-$56.52 M
|
-$59.88 M
|
-$65.98 M
|
-$38.39 M
|
-$48.56 M
|
-$38.64 M
|
-$18.23 M
|
| Net Income Ratio |
0
|
0
|
0
|
-39.03
|
-90.45
|
-73.15
|
-2.37
|
-195
|
-529.34
|
-387.79
|
| EPS |
-7.18 |
49.3 |
-56.63 |
-33.66 |
-38.27 |
-57.01 |
-40.92 |
-57.38 |
-63.45 |
-56.46 |
| EPS Diluted |
-7.18 |
49.3 |
-56.63 |
-33.66 |
-38.27 |
-57.01 |
-40.92 |
-57.38 |
-63.45 |
-56.46 |
| Weighted Average Shares Out |
$3.26 M
|
$1.99 M
|
$1.99 M
|
$1.68 M
|
$1.56 M
|
$1.16 M
|
$938,213.00
|
$846,265.00
|
$609,022.00
|
$322,838.00
|
| Weighted Average Shares Out Diluted |
$3.26 M
|
$1.99 M
|
$1.99 M
|
$1.68 M
|
$1.56 M
|
$1.16 M
|
$938,213.00
|
$846,265.00
|
$609,022.00
|
$322,838.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
